Skip to main content
NCBI home page
Tobacco Control logoLink to Tobacco Control
. 2003 Dec;12(4):349–359. doi: 10.1136/tc.12.4.349

Effect of smokeless tobacco (snus) on smoking and public health in Sweden

J Foulds 1, L Ramstrom 1, M Burke 1, K Fagerstrom 1
PMCID: PMC1747791  PMID: 14660766

Abstract

Method: Narrative review of published papers and other data sources (for example, conference abstracts and internet based information) on snus use, use of other tobacco products, and changes in health status in Sweden.

Results: Snus is manufactured and stored in a manner that causes it to deliver lower concentrations of some harmful chemicals than other tobacco products, although it can deliver high doses of nicotine. It is dependence forming, but does not appear to cause cancer or respiratory diseases. It may cause a slight increase in cardiovascular risks and is likely to be harmful to the unborn fetus, although these risks are lower than those caused by smoking. There has been a larger drop in male daily smoking (from 40% in 1976 to 15% in 2002) than female daily smoking (34% in 1976 to 20% in 2002) in Sweden, with a substantial proportion (around 30%) of male ex-smokers using snus when quitting smoking. Over the same time period, rates of lung cancer and myocardial infarction have dropped significantly faster among Swedish men than women and remain at low levels as compared with other developed countries with a long history of tobacco use.

Conclusions: Snus availability in Sweden appears to have contributed to the unusually low rates of smoking among Swedish men by helping them transfer to a notably less harmful form of nicotine dependence.

Full Text

The Full Text of this article is available as a PDF (476.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Accortt Neil A., Waterbor John W., Beall Colleen, Howard George. Chronic disease mortality in a cohort of smokeless tobacco users. Am J Epidemiol. 2002 Oct 15;156(8):730–737. doi: 10.1093/aje/kwf106. [DOI] [PubMed] [Google Scholar]
  2. Andersson G., Björnberg G., Curvall M. Oral mucosal changes and nicotine disposition in users of Swedish smokeless tobacco products: a comparative study. J Oral Pathol Med. 1994 Apr;23(4):161–167. doi: 10.1111/j.1600-0714.1994.tb01106.x. [DOI] [PubMed] [Google Scholar]
  3. Asplund Kjell, Nasic Salmir, Janlert Urban, Stegmayr Birgitta. Smokeless tobacco as a possible risk factor for stroke in men: a nested case-control study. Stroke. 2003 May 29;34(7):1754–1759. doi: 10.1161/01.STR.0000076011.02935.A1. [DOI] [PubMed] [Google Scholar]
  4. Asplund Kjell. Smokeless tobacco and cardiovascular disease. Prog Cardiovasc Dis. 2003 Mar-Apr;45(5):383–394. doi: 10.1053/pcad.2003.00102. [DOI] [PubMed] [Google Scholar]
  5. Bates C. Clearing the smoke or muddying the water? Tob Control. 2001 Jun;10(2):87–88. doi: 10.1136/tc.10.2.87. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bates C., Fagerström K., Jarvis M. J., Kunze M., McNeill A., Ramström L. European Union policy on smokeless tobacco: a statement in favour of evidence based regulation for public health. Tob Control. 2003 Dec;12(4):360–367. doi: 10.1136/tc.12.4.360. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Benowitz N. L. Snuff, nicotine and cardiovascular disease: implications for tobacco control. J Am Coll Cardiol. 1999 Nov 15;34(6):1791–1793. doi: 10.1016/s0735-1097(99)00415-5. [DOI] [PubMed] [Google Scholar]
  8. Bolinder G. M., Ahlborg B. O., Lindell J. H. Use of smokeless tobacco: blood pressure elevation and other health hazards found in a large-scale population survey. J Intern Med. 1992 Oct;232(4):327–334. doi: 10.1111/j.1365-2796.1992.tb00593.x. [DOI] [PubMed] [Google Scholar]
  9. Bolinder G., Alfredsson L., Englund A., de Faire U. Smokeless tobacco use and increased cardiovascular mortality among Swedish construction workers. Am J Public Health. 1994 Mar;84(3):399–404. doi: 10.2105/ajph.84.3.399. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Bolinder G., Norén A., Wahren J., De Faire U. Long-term use of smokeless tobacco and physical performance in middle-aged men. Eur J Clin Invest. 1997 May;27(5):427–433. doi: 10.1046/j.1365-2362.1997.1290677.x. [DOI] [PubMed] [Google Scholar]
  11. Bolinder G., Norén A., de Faire U., Wahren J. Smokeless tobacco use and atherosclerosis: an ultrasonographic investigation of carotid intima media thickness in healthy middle-aged men. Atherosclerosis. 1997 Jul 11;132(1):95–103. doi: 10.1016/s0021-9150(97)00075-0. [DOI] [PubMed] [Google Scholar]
  12. Bolinder G., de Faire U. Ambulatory 24-h blood pressure monitoring in healthy, middle-aged smokeless tobacco users, smokers, and nontobacco users. Am J Hypertens. 1998 Oct;11(10):1153–1163. doi: 10.1016/s0895-7061(98)00137-x. [DOI] [PubMed] [Google Scholar]
  13. Brunnemann K. D., Qi J., Hoffmann D. Chemical profile of two types of oral snuff tobacco. Food Chem Toxicol. 2002 Nov;40(11):1699–1703. doi: 10.1016/s0278-6915(02)00134-5. [DOI] [PubMed] [Google Scholar]
  14. Critchley J. A., Unal B. Health effects associated with smokeless tobacco: a systematic review. Thorax. 2003 May;58(5):435–443. doi: 10.1136/thorax.58.5.435. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Curvall M., Romert L., Norlén E., Enzell C. R. Mutagen levels in urine from snuff users, cigarette smokers and non tobacco users--a comparison. Mutat Res. 1987 Jun;188(2):105–110. doi: 10.1016/0165-1218(87)90098-x. [DOI] [PubMed] [Google Scholar]
  16. Eliasson M., Asplund K., Evrin P. E., Lundblad D. Relationship of cigarette smoking and snuff dipping to plasma fibrinogen, fibrinolytic variables and serum insulin. The Northern Sweden MONICA Study. Atherosclerosis. 1995 Feb;113(1):41–53. doi: 10.1016/0021-9150(94)05425-i. [DOI] [PubMed] [Google Scholar]
  17. Ernst M., Moolchan E. T., Robinson M. L. Behavioral and neural consequences of prenatal exposure to nicotine. J Am Acad Child Adolesc Psychiatry. 2001 Jun;40(6):630–641. doi: 10.1097/00004583-200106000-00007. [DOI] [PubMed] [Google Scholar]
  18. Fant R. V., Henningfield J. E., Nelson R. A., Pickworth W. B. Pharmacokinetics and pharmacodynamics of moist snuff in humans. Tob Control. 1999 Winter;8(4):387–392. doi: 10.1136/tc.8.4.387. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Galanti M. R., Wickholm S., Gilljam H. Between harm and dangers. Oral snuff use, cigarette smoking and problem behaviours in a survey of Swedish male adolescents. Eur J Public Health. 2001 Sep;11(3):340–345. doi: 10.1093/eurpub/11.3.340. [DOI] [PubMed] [Google Scholar]
  20. Henningfield J. E., Fagerstrom K. O. Swedish Match Company, Swedish snus and public health: a harm reduction experiment in progress? Tob Control. 2001 Sep;10(3):253–257. doi: 10.1136/tc.10.3.253. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Henningfield J. E., Keenan R. M. Nicotine delivery kinetics and abuse liability. J Consult Clin Psychol. 1993 Oct;61(5):743–750. doi: 10.1037//0022-006x.61.5.743. [DOI] [PubMed] [Google Scholar]
  22. Hirsch J. M., Livian G., Edward S., Noren J. G. Tobacco habits among teenagers in the city of Göteborg, Sweden, and possible association with dental caries. Swed Dent J. 1991;15(3):117–123. [PubMed] [Google Scholar]
  23. Hoffmann D., Djordjevic M. V., Fan J., Zang E., Glynn T., Connolly G. N. Five leading U.S. commercial brands of moist snuff in 1994: assessment of carcinogenic N-nitrosamines. J Natl Cancer Inst. 1995 Dec 20;87(24):1862–1869. doi: 10.1093/jnci/87.24.1862. [DOI] [PubMed] [Google Scholar]
  24. Holm H., Jarvis M. J., Russell M. A., Feyerabend C. Nicotine intake and dependence in Swedish snuff takers. Psychopharmacology (Berl) 1992;108(4):507–511. doi: 10.1007/BF02247429. [DOI] [PubMed] [Google Scholar]
  25. Huhtasaari F., Asplund K., Lundberg V., Stegmayr B., Wester P. O. Tobacco and myocardial infarction: is snuff less dangerous than cigarettes? BMJ. 1992 Nov 21;305(6864):1252–1256. doi: 10.1136/bmj.305.6864.1252. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Huhtasaari F., Lundberg V., Eliasson M., Janlert U., Asplund K. Smokeless tobacco as a possible risk factor for myocardial infarction: a population-based study in middle-aged men. J Am Coll Cardiol. 1999 Nov 15;34(6):1784–1790. doi: 10.1016/s0735-1097(99)00409-x. [DOI] [PubMed] [Google Scholar]
  27. Idris A. M., Ibrahim S. O., Vasstrand E. N., Johannessen A. C., Lillehaug J. R., Magnusson B., Wallström M., Hirsch J. M., Nilsen R. The Swedish snus and the Sudanese toombak: are they different? Oral Oncol. 1998 Nov;34(6):558–566. doi: 10.1016/s1368-8375(98)00047-5. [DOI] [PubMed] [Google Scholar]
  28. Idris A. M., Nair J., Ohshima H., Friesen M., Brouet I., Faustman E. M., Bartsch H. Unusually high levels of carcinogenic tobacco-specific nitrosamines in Sudan snuff (toombak). Carcinogenesis. 1991 Jun;12(6):1115–1118. doi: 10.1093/carcin/12.6.1115. [DOI] [PubMed] [Google Scholar]
  29. Kozlowski Lynn T., O'Connor Richard J., Edwards Beth Quinio, Flaherty Brian P. Most smokeless tobacco use is not a causal gateway to cigarettes: using order of product use to evaluate causation in a national US sample. Addiction. 2003 Aug;98(8):1077–1085. doi: 10.1046/j.1360-0443.2003.00460.x. [DOI] [PubMed] [Google Scholar]
  30. Lagergren J., Bergström R., Lindgren A., Nyrén O. The role of tobacco, snuff and alcohol use in the aetiology of cancer of the oesophagus and gastric cardia. Int J Cancer. 2000 Feb 1;85(3):340–346. [PubMed] [Google Scholar]
  31. Lewin F., Norell S. E., Johansson H., Gustavsson P., Wennerberg J., Biörklund A., Rutqvist L. E. Smoking tobacco, oral snuff, and alcohol in the etiology of squamous cell carcinoma of the head and neck: a population-based case-referent study in Sweden. Cancer. 1998 Apr 1;82(7):1367–1375. doi: 10.1002/(sici)1097-0142(19980401)82:7<1367::aid-cncr21>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
  32. Lundbäck B., Lindberg A., Lindström M., Rönmark E., Jonsson A. C., Jönsson E., Larsson L. G., Andersson S., Sandström T., Larsson K. Not 15 but 50% of smokers develop COPD?--Report from the Obstructive Lung Disease in Northern Sweden Studies. Respir Med. 2003 Feb;97(2):115–122. doi: 10.1053/rmed.2003.1446. [DOI] [PubMed] [Google Scholar]
  33. McNeill A., Foulds J., Bates C. Regulation of nicotine replacement therapies (NRT): a critique of current practice. Addiction. 2001 Dec;96(12):1757–1768. doi: 10.1080/09652140120089508. [DOI] [PubMed] [Google Scholar]
  34. Merne M. E., Tiekso J. T., Syrjänen S. M. Snuff use and smoking among senior high school students: effects of a snuff sales ban. Oral Dis. 1998 Sep;4(3):207–212. doi: 10.1111/j.1601-0825.1998.tb00280.x. [DOI] [PubMed] [Google Scholar]
  35. Nilsson R. A qualitative and quantitative risk assessment of snuff dipping. Regul Toxicol Pharmacol. 1998 Aug;28(1):1–16. doi: 10.1006/rtph.1998.1229. [DOI] [PubMed] [Google Scholar]
  36. Osterdahl B. G., Slorach S. A. Volatile N-nitrosamines in snuff and chewing tobacco on the Swedish market. Food Chem Toxicol. 1983 Dec;21(6):759–762. doi: 10.1016/0278-6915(83)90210-7. [DOI] [PubMed] [Google Scholar]
  37. Persson P. G., Carlsson S., Svanström L., Ostenson C. G., Efendic S., Grill V. Cigarette smoking, oral moist snuff use and glucose intolerance. J Intern Med. 2000 Aug;248(2):103–110. doi: 10.1046/j.1365-2796.2000.00708.x. [DOI] [PubMed] [Google Scholar]
  38. Rodu B., Stegmayr B., Nasic S., Asplund K. Impact of smokeless tobacco use on smoking in northern Sweden. J Intern Med. 2002 Nov;252(5):398–404. doi: 10.1046/j.1365-2796.2002.01057.x. [DOI] [PubMed] [Google Scholar]
  39. Rodu B., Stegmayr B., Nasic S., Cole P., Asplund K. Evolving patterns of tobacco use in northern Sweden. J Intern Med. 2003 Jun;253(6):660–665. doi: 10.1046/j.1365-2796.2003.01143.x. [DOI] [PubMed] [Google Scholar]
  40. Rosén M., Alfredsson L., Hammar N., Kahan T., Spetz C. L., Ysberg A. S. Attack rate, mortality and case fatality for acute myocardial infarction in Sweden during 1987-95. Results from the national AMI register in Sweden. J Intern Med. 2000 Aug;248(2):159–164. doi: 10.1046/j.1365-2796.2000.00716.x. [DOI] [PubMed] [Google Scholar]
  41. Russell M. A., Jarvis M. J., Feyerabend C., Fernö O. Nasal nicotine solution: a potential aid to giving up smoking? Br Med J (Clin Res Ed) 1983 Feb 26;286(6366):683–684. doi: 10.1136/bmj.286.6366.683. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Schildt E. B., Eriksson M., Hardell L., Magnuson A. Oral snuff, smoking habits and alcohol consumption in relation to oral cancer in a Swedish case-control study. Int J Cancer. 1998 Jul 29;77(3):341–346. doi: 10.1002/(sici)1097-0215(19980729)77:3<341::aid-ijc6>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]
  43. West R., Hajek P., Foulds J., Nilsson F., May S., Meadows A. A comparison of the abuse liability and dependence potential of nicotine patch, gum, spray and inhaler. Psychopharmacology (Berl) 2000 Apr;149(3):198–202. doi: 10.1007/s002130000382. [DOI] [PubMed] [Google Scholar]
  44. Ye W., Ekström A. M., Hansson L. E., Bergström R., Nyrén O. Tobacco, alcohol and the risk of gastric cancer by sub-site and histologic type. Int J Cancer. 1999 Oct 8;83(2):223–229. doi: 10.1002/(sici)1097-0215(19991008)83:2<223::aid-ijc13>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]

Articles from Tobacco Control are provided here courtesy of BMJ Publishing Group

RESOURCES